| Identification | Back Directory | [Name]
A 71623 | [CAS]
130408-77-4 | [Synonyms]
A 71623
N-Boc-L-Trp-[(2S)-2-Amino*-6-[3-(2-methylphenyl)ureido]hexanoyl]-L-Asp-N-methyl-L-Phe-NH2
N-[(1,1-Dimethylethoxy)carbonyl]-L-tryptophyl-N6-[[(2-methylphenyl)amino]carbonyl]-L-lysyl-L-α-aspartyl-Nα-methyl-L-phenylalaninamide
L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tryptophyl-N6-[[(2-methylphenyl)amino]carbonyl]-L-lysyl-L-α-aspartyl-Nα-methyl-
N-[(1,1-DIMETHYLETHOXY)CARBONYL]-L-TRYPTOPHYL-N6-[[(2-METHYLPHENYL)AMINO]CARBONYL]-L-LYSYL-L-ALPHA-ASPARTYL-NA-METHYL-L-PHENYLALANINAMIDE | [Molecular Formula]
C44H56N8O9 | [MDL Number]
MFCD00897724 | [MOL File]
130408-77-4.mol | [Molecular Weight]
840.96 |
| Hazard Information | Back Directory | [Uses]
A-71623 is a potent CCK agonist with 1200-fold selectivity over the CCK2 receptor. | [Biological Activity]
Potent CCK 1 agonist (IC 50 = 3.7 nM) with 1200-fold selectivity over the CCK 2 receptor. Suppresses food intake following central or peripheral administration. | [in vivo]
A71623 (A-63387; i.c.v., but not i.p., injections) reduces food intakes and suppresses intakes of a liquid diet in both deprived and sated rats[2].
A71623 dampens Purkinje neuron pathology and associates deficits in motor performance in Pcp2-ATXN1[30Q]D776;Cck-/- and Pcp2-AXTN1[82Q] mice[3].
A71623 improves motor performance of Pcp2-ATXN2[127Q] SCA2 mice[3]. | Animal Model: | Adult male, Sprague-Dawley rats[2] | | Dosage: | 5 μL | | Administration: | Intracerebroventricular (i.c.v) administration, A-71623 was infused using a 28 gauge injection cannula in a volume of 5uL over 60 s | | Result: | Reduced food intakes and suppressed intakes of a liquid diet.
|
| Animal Model: | ATXN1[30Q]-D776, ATXN1[82Q]-D776, ATXN2[127Q], and WT/FVB/NJ mice [3] | | Dosage: | 0.02 mg/kg/day | | Administration: | Osmotic minipumps containing either A71623 (0.02mg/kg/day) were implanted intraperitoneally (i.p.) | | Result: | Treatment dampened Purkinje neuron pathology in ATXN1[30Q]D776;Cck-/- mice and ATXN1[82Q] mice.
Improved motor performance in ATXN2[127Q] mice.
|
| [IC 50]
CCKAR | [storage]
Store at -20°C | [References]
[1]. gracey dj, bell r, king dj. differential effects of the ccka receptor ligands pd-140,548 and a-71623 on latent inhibition in the rat. progress in neuro-psychopharmacology and biological psychiatry, 2002, 26(3): 497-504.
[2]. lin cw, shiosaki k, miller tr, et al. characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, a-71623 and a-70874, that exhibit high potency and selectivity for cholecystokinin-a receptors. molecular pharmacology, 1991, 39(3): 346-351.
[3]. kaufmann r, lindschau c, scho t, et al. type b cholecystokinin receptors on rat glioma c6 cells. binding studies and measurement of intracellular calcium mobilization. brain research, 1994, 639(1): 109-114. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|